| Autor: |
Herndon, Justine, Gupta, Nidhi, Davidge-Pitts, Caroline, Imhof, Nicole, Gonzalez, Cesar, Carlson, Sara, Will, Marissa, Martinez-Jorge, Jorys, Fahradyan, Vahe, Tamire, Lily, Lin, Anna, Nippoldt, Todd B, Chang, Alice Y |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Endocrinology & Metabolism; Nov2024, Vol. 109 Issue 11, p2774-2783, 10p |
| Abstrakt: |
Context Transgender and gender diverse (TGD) individuals have greater access to genital surgery (GS) with improved insurance coverage and access to trained surgeons and interdisciplinary gender-affirming providers. Objective To determine perioperative medical and behavioral health outcomes in transfeminine (TF) individuals undergoing GS, with use of a specific gender-affirming hormone therapy (GAHT) algorithm based on individualized risk factor assessment. Methods In this retrospective observational cohort study, we collected preoperative and postoperative data from 183 TF individuals at a single tertiary referral center from 2017 to 2022, grouping patients by those who continued estradiol (Group 1) vs those who had temporarily discontinued estradiol for 2 to 6 weeks preoperatively (Group 2). Data included clinical and biochemical assessment, GAHT regimens, validated behavioral health measures, and postoperative complications. Main outcomes included venous thromboembolism (VTE) incidence, non-VTE postoperative complication incidence, and change in behavioral health assessments. Results The majority of individuals continued estradiol perioperatively (Group 1; 138 [75.4%]). Individuals who temporarily held estradiol preoperatively (Group 2; 45 [24.6%]) were statistically older (P <.01), had higher incidence of cardiometabolic comorbidities (P <.01), and higher Caprini scores (P <.01). Group 1 was statistically more likely to use oral estradiol (P <.01). One episode (0.05%) of VTE occurred (Group 1). There was no significant difference in postoperative complications or behavioral health measures between groups. Conclusion An individualized algorithm for preoperative hormone management for TF GS resulted in perioperative continuation of GAHT for the majority of individuals without significantly increasing the risk for postoperative surgical complications, while maintaining stable behavioral health measures perioperatively. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
